Message #28 From:
Stock News Bot Date: February 3, 2009 09:08:42 AM
PYTO PhytoMedical’s Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer PhytoMedical’s compound for difficult-to-treat human brain cancer reveals case of “tumor cured”; demonstrates prolonged survival rat
PhytoMedical’s Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer
PhytoMedical’s compound for difficult-to-treat human brain cancer
reveals case of “tumor cured”; demonstrates prolonged survival rates,
enhanced chemotherapeutic effect, and inhibited growth of SF295 human
glioblastoma
PhytoMedical Technologies, Inc. (OTCBB: PYTO stocks news) (FWB: ET6), today
announced favorable results from recent in vivo efficacy and toxicity
tests where the Company’s patented anti-cancer compound was administered
to specimens with difficult-to-treat human brain cancer (SF295
glioblastoma xenografts) and, according to researchers, proved to be
least toxic and extremely effective in controlling the growth of SF295
human glioblastoma xenografts.
In all cases where specimens were treated for human glioblastoma brain
cancer using PhytoMedical’s patented compound, researchers reported: a
significant reduction in tumor size; prolonged lifespan of 46%-plus for
the treated group versus the control group; notably enhanced
chemotherapeutic effect of the compound; and even observed “tumor cured”
in one of the specimens with the deadly glioblastoma cancer.
Interpreting the data collected from these important efficacy and
toxicity tests, researchers favorably surmised that PhytoMedical’s
anti-cancer compound may “…have its selectivity in killing SF295 human
glioblastoma cells.” In contrast, broad anti-cancer treatments may be
less effective and carry greater risks and side-effects than compounds
with the key ability to selectively target and kill specific cancer
cells -- an important consideration for the treatment of cancers in
vital organs such as the brain, where glioblastoma is exhibited.
Glioblastoma is the most common and aggressive form of brain cancer, and
is often highly-resistant to chemotherapy and other conventional
treatments, meaning there is no current cure. Additionally, surgical
removal such as complete resection of the tumor in combination with the
most current and aggressive treatments continues to result in low
survival rates.
“There’s little doubt that glioblastoma brain cancer is a
difficult-to-treat cancer, yet our test results have been
highly-favorable. I am elated by the results of our latest phase of
efficacy and toxicity tests. The fact that one of the test specimens
exhibited tumor cured with no negative side-effects is groundbreaking
and especially encouraging,” stated Mr. Greg Wujek, President and CEO of
PhytoMedical Technologies, Inc. “From here we continue to build on our
early success and move to the next phase of development with bolstered
confidence.”
“We’re now reviewing our formulation options and very much look forward
to continuing our anti-cancer drug development with the hope of
producing an effective treatment option against glioblastoma, a deadly
disease.” The median survival time from the time of glioblastoma
diagnosis for patients without treatment is 3 months. Currently, as few
as 1 in 20 patients will survive beyond 36 months, and only 1 in 5,000
will survive for decades.
PhytoMedical’s Cancer Research:
Killing Cancer’s DNA
Led by Dartmouth College researcher, Dr. Gordon Gribble, PhytoMedical is
developing a novel class of patented anti-cancer agents that have a
‘cytotoxic’ or poisonous affinity for cancer cells and are designed to
bind more tightly to cancer cell DNA than many conventional anticancer
drugs by a process called bis-intercalation or “double binding,” much
like a molecular staple. Because the DNA is the blueprint of life for
the cancer cell, such binding stops the replication of the DNA, which
prevents the growth of the cancer cell and it dies.
DNA is present in the nucleus of every cell of all living organisms,
which are constantly dividing through a process in which the DNA in the
nucleus of the original cell replicates itself to be present in the
nuclei of the two new (“daughter”) cells. If this replication cannot
occur, the cell will die and the organism will eventually stop growing
and die. Cancer is characterized by the development of abnormal cells
that divide uncontrollably and have the ability to infiltrate and
destroy normal body tissue.
At present, anticancer molecules designed to block the replication of
DNA do so through “intercalation,” a mechanism in which the drug inserts
itself between one set of adjacent base pairs of the DNA. PhytoMedical
believes a more effective anticancer strategy is to design molecules
(“bis-intercalators”) that can intercalate simultaneously at two DNA
sites, thus further increasing the binding between the drug and the DNA
of specific cancer cells in order to stop their replication and
ultimately resulting in the death of the cancer cell.
This compound is derived from anti-cancer agents, claimed in Dartmouth
United States Patent patent No.: 6,187,787, for which PhytoMedical holds
an exclusive license. "These promising results are an eloquent testimony
to the importance of academic collaboration with industry leading to the
development of products beneficial to the society," said Alla Kan,
Director of Dartmouth's Technology Transfer Office.
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange:
ET6), together with its wholly owned subsidiaries, is a pharmaceutical
company focused on research, development and commercialization of
pharmaceutical products.
For additional information, please visit www.PhytoMedical.com
To receive future press releases via email, please visit:
http://www.phytomedical.com/investors.php
To view the full HTML text of this release, please visit:
No statement herein should be considered an offer or a solicitation of
an offer for the purchase or sale of any securities. This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about future
events. Although the Company believes that the expectations reflected in
the forward-looking statements and the assumptions upon which they are
based are reasonable, it can give no assurance that such expectations
and assumptions will prove to have been correct. Forward-looking
statements, which involve assumptions and describe our future plans,
strategies, and expectations, are generally identifiable by use of the
words “may,” “will,” “should,” “could,” “expect,” “anticipate,”
“estimate,” “believe,” “intend,” or “project” or the negative of these
words or other variations on these words or comparable terminology. The
reader is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to adverse economic conditions,
intense competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, inadequate capital, unexpected costs and operating deficits,
increases in general and administrative costs, termination of contracts
or agreements, technological obsolescence of the Company's products,
technical problems with the Company's research and products, price
increases for supplies and components, litigation and administrative
proceedings involving the Company, the possible acquisition of new
businesses or technologies that result in operating losses or that do
not perform as anticipated, unanticipated losses, the possible
fluctuation and volatility of the Company's operating results, financial
condition and stock price, losses incurred in litigating and settling
cases, dilution in the Company's ownership of its business, adverse
publicity and news coverage, inability to carry out research,
development and commercialization plans, loss or retirement of key
executives and research scientists, changes in interest rates,
inflationary factors, and other specific risks. We currently have no
commercial products intended to diagnose, treat, prevent or cure any
disease. The statements contained in this press release regarding our on
going research and development and the results attained by us to-date
have not been evaluated by the Food and Drug Administration. There can
be no assurance that further research and development, and /or whether
clinical trial results, if any, will validate and support the results of
our preliminary research and studies. Further, there can be no assurance
that the necessary regulatory approvals will be obtained or that
PhytoMedical will be able to develop commercially viable products on the
basis of its technologies. In addition, other factors that could cause
actual results to differ materially are discussed in the Company's most
recent Form 10-QSB and Form 10-KSB filings with the Securities and
Exchange Commission. These reports and filings may be inspected and
copied at the Public Reference Room maintained by the U.S. Securities &
Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You
can obtain information about operation of the Public Reference Room by
calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The
U.S. Securities & Exchange Commission also maintains an Internet site
that contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the U.S.
Securities & Exchange Commission at http://www.sec.gov.
The Company undertakes no obligation to publicly release the results of
any revisions to these forward looking statements that may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.
PhytoMedical Technologies, Inc. Mr. Greg Wujek, 800-611-3388 President
& CEO www.PhytoMedical.com
